Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Quinolines | 3 | 2024 | 156 | 1.470 |
Why?
|
| Triazoles | 3 | 2021 | 148 | 1.390 |
Why?
|
| Microbial Sensitivity Tests | 5 | 2021 | 349 | 0.880 |
Why?
|
| DNA Helicases | 5 | 2025 | 146 | 0.840 |
Why?
|
| Antineoplastic Agents | 8 | 2024 | 2045 | 0.830 |
Why?
|
| Structure-Activity Relationship | 11 | 2024 | 549 | 0.790 |
Why?
|
| Isatin | 1 | 2021 | 1 | 0.720 |
Why?
|
| Glucuronidase | 1 | 2019 | 44 | 0.660 |
Why?
|
| DNA-Binding Proteins | 5 | 2025 | 1441 | 0.650 |
Why?
|
| Molecular Structure | 10 | 2021 | 483 | 0.610 |
Why?
|
| Anti-Bacterial Agents | 4 | 2021 | 1708 | 0.590 |
Why?
|
| Methicillin-Resistant Staphylococcus aureus | 1 | 2021 | 221 | 0.570 |
Why?
|
| Glycoproteins | 1 | 2019 | 338 | 0.560 |
Why?
|
| Glycoside Hydrolase Inhibitors | 2 | 2024 | 3 | 0.410 |
Why?
|
| Hypoglycemic Agents | 4 | 2024 | 1221 | 0.390 |
Why?
|
| Dose-Response Relationship, Drug | 6 | 2021 | 2016 | 0.370 |
Why?
|
| Thiadiazoles | 2 | 2021 | 25 | 0.350 |
Why?
|
| Cell Survival | 3 | 2024 | 1086 | 0.350 |
Why?
|
| Antitubercular Agents | 2 | 2024 | 200 | 0.340 |
Why?
|
| Aminoquinolines | 2 | 2020 | 21 | 0.340 |
Why?
|
| Molecular Docking Simulation | 4 | 2024 | 109 | 0.330 |
Why?
|
| Breast Neoplasms | 2 | 2024 | 2104 | 0.320 |
Why?
|
| Oxadiazoles | 2 | 2020 | 33 | 0.320 |
Why?
|
| Coumarins | 2 | 2020 | 20 | 0.320 |
Why?
|
| Antifungal Agents | 2 | 2020 | 130 | 0.320 |
Why?
|
| Pyrimidines | 2 | 2024 | 458 | 0.300 |
Why?
|
| Pyrazoles | 2 | 2024 | 403 | 0.300 |
Why?
|
| Anti-Infective Agents | 2 | 2021 | 249 | 0.290 |
Why?
|
| Indoles | 2 | 2020 | 387 | 0.280 |
Why?
|
| Drug Screening Assays, Antitumor | 3 | 2021 | 191 | 0.250 |
Why?
|
| Drug Design | 3 | 2022 | 158 | 0.240 |
Why?
|
| alpha-Glucosidases | 2 | 2024 | 12 | 0.240 |
Why?
|
| Enzyme Inhibitors | 2 | 2019 | 827 | 0.240 |
Why?
|
| DNA Damage | 2 | 2024 | 383 | 0.240 |
Why?
|
| Drug Synergism | 1 | 2024 | 370 | 0.220 |
Why?
|
| MCF-7 Cells | 2 | 2021 | 114 | 0.210 |
Why?
|
| Plants, Medicinal | 1 | 2021 | 22 | 0.190 |
Why?
|
| Chalcones | 1 | 2021 | 9 | 0.190 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2024 | 808 | 0.190 |
Why?
|
| Thiazolidines | 1 | 2021 | 9 | 0.190 |
Why?
|
| alpha-Amylases | 1 | 2021 | 16 | 0.180 |
Why?
|
| Triple Negative Breast Neoplasms | 1 | 2024 | 193 | 0.180 |
Why?
|
| Neoplasms | 3 | 2025 | 2454 | 0.180 |
Why?
|
| Mycobacterium tuberculosis | 2 | 2024 | 309 | 0.180 |
Why?
|
| HEK293 Cells | 2 | 2020 | 697 | 0.170 |
Why?
|
| Pyrimidinones | 1 | 2021 | 102 | 0.170 |
Why?
|
| Chemistry Techniques, Synthetic | 1 | 2020 | 14 | 0.170 |
Why?
|
| Isoniazid | 1 | 2020 | 63 | 0.170 |
Why?
|
| Isoindoles | 1 | 2019 | 4 | 0.170 |
Why?
|
| Glutamine-Fructose-6-Phosphate Transaminase (Isomerizing) | 1 | 2019 | 1 | 0.170 |
Why?
|
| Antimalarials | 1 | 2019 | 30 | 0.160 |
Why?
|
| Plasmodium falciparum | 1 | 2019 | 30 | 0.160 |
Why?
|
| beta-Lactams | 1 | 2020 | 28 | 0.160 |
Why?
|
| Malaria | 1 | 2019 | 59 | 0.160 |
Why?
|
| Fungi | 1 | 2020 | 136 | 0.150 |
Why?
|
| Small Molecule Libraries | 1 | 2019 | 86 | 0.150 |
Why?
|
| Cell Proliferation | 3 | 2021 | 2378 | 0.150 |
Why?
|
| Cell Line, Tumor | 5 | 2024 | 3185 | 0.140 |
Why?
|
| Anti-Inflammatory Agents | 1 | 2021 | 482 | 0.140 |
Why?
|
| Colorectal Neoplasms | 1 | 2024 | 748 | 0.140 |
Why?
|
| Humans | 19 | 2025 | 129847 | 0.130 |
Why?
|
| Pyridines | 1 | 2019 | 478 | 0.120 |
Why?
|
| Computer Simulation | 1 | 2020 | 941 | 0.120 |
Why?
|
| Bacteria | 1 | 2020 | 814 | 0.110 |
Why?
|
| Pancreatic Neoplasms | 1 | 2020 | 879 | 0.100 |
Why?
|
| Binding Sites | 2 | 2019 | 1251 | 0.060 |
Why?
|
| Diabetes Mellitus, Type 2 | 1 | 2018 | 2444 | 0.050 |
Why?
|
| Fluorouracil | 1 | 2024 | 197 | 0.050 |
Why?
|
| Poly(ADP-ribose) Polymerase Inhibitors | 1 | 2024 | 90 | 0.050 |
Why?
|
| Drug Repositioning | 1 | 2021 | 26 | 0.050 |
Why?
|
| Oncogenes | 1 | 2022 | 110 | 0.050 |
Why?
|
| Protease Inhibitors | 1 | 2021 | 107 | 0.040 |
Why?
|
| Peptide Hydrolases | 1 | 2021 | 108 | 0.040 |
Why?
|
| Female | 3 | 2024 | 68829 | 0.040 |
Why?
|
| Antioxidants | 1 | 2024 | 558 | 0.040 |
Why?
|
| Carcinogenesis | 1 | 2022 | 214 | 0.040 |
Why?
|
| Parasitic Sensitivity Tests | 1 | 2019 | 2 | 0.040 |
Why?
|
| Candida albicans | 1 | 2020 | 54 | 0.040 |
Why?
|
| Ciprofloxacin | 1 | 2019 | 30 | 0.040 |
Why?
|
| Microwaves | 1 | 2019 | 36 | 0.040 |
Why?
|
| Drug Resistance, Multiple, Bacterial | 1 | 2019 | 72 | 0.040 |
Why?
|
| Heme | 1 | 2019 | 77 | 0.040 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2019 | 171 | 0.040 |
Why?
|
| Fructose-Bisphosphatase | 1 | 2018 | 1 | 0.040 |
Why?
|
| Phosphoenolpyruvate Carboxykinase (ATP) | 1 | 2018 | 15 | 0.040 |
Why?
|
| Dipeptidyl Peptidase 4 | 1 | 2018 | 13 | 0.040 |
Why?
|
| Sodium-Glucose Transporter 2 | 1 | 2018 | 22 | 0.040 |
Why?
|
| Animals | 3 | 2025 | 35409 | 0.040 |
Why?
|
| Receptors, Glucagon | 1 | 2018 | 27 | 0.040 |
Why?
|
| Protein Tyrosine Phosphatase, Non-Receptor Type 1 | 1 | 2018 | 47 | 0.040 |
Why?
|
| Estrogen Receptor alpha | 1 | 2018 | 130 | 0.030 |
Why?
|
| Mice | 2 | 2024 | 16983 | 0.030 |
Why?
|
| Pseudomonas aeruginosa | 1 | 2020 | 348 | 0.030 |
Why?
|
| PPAR gamma | 1 | 2018 | 183 | 0.030 |
Why?
|
| Receptors, G-Protein-Coupled | 1 | 2018 | 207 | 0.030 |
Why?
|
| Antineoplastic Combined Chemotherapy Protocols | 1 | 2024 | 1560 | 0.030 |
Why?
|
| Antiviral Agents | 1 | 2021 | 719 | 0.030 |
Why?
|
| Apoptosis | 1 | 2024 | 2489 | 0.030 |
Why?
|
| ErbB Receptors | 1 | 2018 | 605 | 0.030 |
Why?
|
| Disease Models, Animal | 1 | 2024 | 4077 | 0.030 |
Why?
|